Semaglutide Pill
Semaglutide Pill is a prescriber-directed weight-management medication option. It should be used as part of a broader care plan that includes nutrition, activity, contraindication screening, and monitoring.
Semaglutide Pill refers to a compounded oral dosage form of semaglutide—the GLP-1 receptor agonist—prepared for patient-specific oral administration. The FDA-approved oral semaglutide (Rybelsus) uses a specialized absorption enhancer (SNAC—sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to facilitate GI absorption of the peptide through the gastric mucosa. Compounded oral semaglutide preparations attempt to replicate this approach, though the bioavailability and pharmacokinetics may differ from the FDA-approved product. Genesis Compounding prepares this as a prescription-only 503A compounded preparation that is not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Semaglutide (prescriber-specified oral dose per tablet/capsule) | GLP-1 receptor agonist providing once-daily oral glucose-dependent insulin stimulation, glucagon suppression, appetite reduction, and gastric motility modulation. |
Route: Oral tablet or capsule, taken once daily.
- Take on an empty stomach (30 minutes before the first meal, drink, or other oral medications of the day). Oral semaglutide absorption is significantly reduced by food, beverages other than plain water, and other medications taken concurrently.
- Swallow whole with up to 120 mL (4 oz) of plain water only—not coffee, juice, or other liquids.
- Do not split, crush, or chew the tablet.
- Remain upright (sitting or standing) for at least 30 minutes after taking.
- Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications.
Prescriber-determined. The FDA-approved oral semaglutide (Rybelsus) titration for type 2 diabetes:
- 3 mg once daily for 30 days (initiation only; this dose is not effective for glycemic control—it is used for GI tolerability).
- 7 mg once daily thereafter; may escalate to 14 mg once daily for additional glycemic control.
- Compounded oral semaglutide dosing should parallel this protocol unless the prescriber specifies otherwise. All dosing is prescriber-determined.
- Semaglutide (oral): Identical pharmacodynamic mechanism to subcutaneous semaglutide—GLP-1 receptor agonism causing glucose-dependent insulin secretion, glucagon suppression, hypothalamic appetite suppression, and delayed gastric emptying. The oral route requires a gastric absorption enhancer (SNAC or equivalent) that locally elevates gastric pH and forms a complex with semaglutide, enabling transcellular transport across gastric epithelium. Oral bioavailability is approximately 1% (highly variable); approximately 3 mg/day yields similar steady-state exposures to subcutaneous 0.5–1.0 mg/week at 14 mg/day doses.
Indication context: Oral semaglutide (Rybelsus) is FDA-approved for type 2 diabetes glycemic management in adults. Compounded oral semaglutide may be prescribed for patients who prefer oral administration over subcutaneous injection. Clinicians should note that oral bioavailability is highly variable and food/drug interactions strictly govern absorption—patient adherence to dosing instructions is critical for efficacy.
Monitoring: Same as injectable semaglutide: HbA1c, body weight, renal function, GI tolerability, and ophthalmologic assessment as indicated.
Safety profile is the same as injectable semaglutide (see IDs 181–184 above). Additional oral-specific considerations:
- Strict fasting requirement: failure to take on an empty stomach with plain water dramatically reduces absorption and may render the dose ineffective.
- Drug absorption interactions are clinically significant: do not co-administer other oral medications within 30 minutes; this is especially important for levothyroxine, oral contraceptives, or drugs with narrow therapeutic windows.
- Same black box warning for thyroid C-cell tumors, and same pancreatitis, retinopathy, and hypoglycemia warnings as injectable semaglutide.
Store at room temperature (15–25°C). Protect from moisture and heat. Keep in the original dispensing container, tightly capped. Do not refrigerate or freeze (unlike injectable formulations). Use within the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.
Why must I take the semaglutide pill on an empty stomach?
Oral semaglutide requires a gastric absorption enhancer to be absorbed through the stomach lining. Food, beverages, and most medications dramatically interfere with this process, reducing bioavailability by up to 90%. A 30-minute fast before and after dosing is essential for consistent absorption.
Can I drink coffee or juice with this medication?
No. Take this medication with plain water only (up to 4 oz / 120 mL). Coffee, juice, tea, or any other beverage will significantly reduce absorption. Return to your normal diet and beverages 30 minutes after taking the dose.
How is the oral pill different from the injectable form?
The active ingredient (semaglutide) and mechanism of action are identical. The difference is delivery: injectable semaglutide bypasses the GI tract for near-complete subcutaneous absorption once weekly; oral semaglutide relies on gastric mucosal absorption and must be taken daily under strict conditions. Injectable semaglutide generally provides more predictable pharmacokinetics.
Is this FDA-approved?
Oral semaglutide (Rybelsus 3 mg, 7 mg, 14 mg) is FDA-approved for type 2 diabetes. This compounded oral preparation is a patient-specific 503A product from Genesis Compounding and is not FDA-approved as a compounded product.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.